Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > News Release

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Nov 16, 2023 9:00am

234 Views

Post# 35738730

RE:RE:News Release

Marcket cap of $90B and ~$350 a share... I think the attempt is to show potential of Antibe if they finally are sucessful and reach the finish line. I'd expect Antibe to hit the editorials/news cycle if PH2 is successful to drum up more eyes.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland